Table: Taisho Pharmaceutical HD - 9-MTH group results
Feb 4 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2020 Dec 31, 2019 Mar 31, 2021
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 214.30 211.34 283.00
(+1.4 pct) (+5.7 pct) (-1.9 pct)
Operating 20.86 17.09 21.00
(+22.1 pct) (-39.2 pct) (-0.7 pct)
Recurring 24.74 20.27 25.50
(+22.0 pct) (-43.9 pct) (+4.2 pct)
Net 14.24 17.79 14.00
(-20.0 pct) (-65.4 pct) (-30.6 pct)
EPS 178.35 yen 222.93 yen 175.42 yen
EPS Diluted 178.12 yen 222.67 yen
Ann Div 110.00 yen 100.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 60.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10